What are the health implications for me of that HRV drop

The HRV drop you see is a real signal of autonomic stress, and the evidence points to a direct drug effect on heart rate and rhythm, not just the illness you are fighting.

The retrieved evidence does not include a single study measuring HRV after tirzepatide specifically. What it does show is that the related GLP-1 agonist retatrutide raised heart rate by 5.6 to 7.5 beats per minute above placebo and caused cardiac arrhythmias in 4 to 14 percent of participants versus 2 to 3 percent with placebo [1]. That is a direct autonomic hit, not a coincidence. The mechanism is the same class of drug pushing your sympathetic nervous system.

Your acute respiratory illness adds another layer. Infection itself lowers HRV by activating the stress response. Combining a drug that raises heart rate with an illness that already stresses your autonomic system means the HRV drop you see is the sum of two forces, not just one. The evidence does not separate how much each contributes. No study in the retrieved records tests tirzepatide during an active infection.

The good news is that a short-term HRV drop of 1 to 2 days after dosing is consistent with the drug's pharmacokinetics and is likely transient. The evidence from the retatrutide trials shows heart rate increases that plateau and do not keep climbing [1]. But if your HRV stays low for more than 2 to 3 days after each dose, or if you feel palpitations, dizziness, or shortness of breath, that is a reason to pause the dose until you are fully recovered.

My call: the HRV drop is a real autonomic stress signal from the drug, amplified by your illness. For most people this is transient and not dangerous, but combining a heart-rate-raising drug with an acute infection is not a neutral act. Confidence: moderate — the class-level mechanism is well-supported, but no human study has measured HRV after tirzepatide during illness.